A Phase 2 interventional study of Tirzepatide and Placebo in Alcohol Use Disorder, Alcohol Abuse/Dependence and Alcohol Dependence, sponsored by Anders Fink-Jensen, MD, DMSci. Recruiting at 2 sites in Denmark. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-02-10.
Sponsored by Anders Fink-Jensen, MD, DMSci · Phase 2, Interventional, and Treatment
How we know · 3 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Alcoholism with a site in Denmark — 7 open to participants now, 11 under way, none of them phase 3. Alcoholism · Denmark.
Among the 29 studies in Alcoholism with a site in Denmark, this one is the 16th largest by planned enrollment, is one of 4 that started in 2025, is one of 7 in phase 2, reaches primary completion later than 8 of the 10 other live ones, and was the 27th registered.
1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.
Browse Alcoholism studies →7 of the 29 studies in Alcoholism with a site in Denmark are open now. Recruiting first, the newest first:
Zealand University Hospital · Sites in Denmark
Ages 18–99
Zealand University Hospital · Sites in Denmark
Ages 18+
Anders Fink-Jensen, MD, DMSci · Sites in Denmark
Ages 30–65
Nina Kimer · Sites in Denmark
Ages 18+
Zealand University Hospital · Sites in Denmark
Ages 18–110
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 108 is above the median of 88 across 1,433 interventional studies indexed under Alcoholism.
Median enrollment 113 across the 29 interventional studies. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 29 has an industry lead sponsor. The 10 most frequent:
Anders Fink-Jensen, MD, DMSci is the lead sponsor of 11 studies on the registry; 3 are open to participants now.
Anders Fink-Jensen, MD, DMSci has 6 studies filed under Alcoholism — fewer than ten, so there is no comparison to draw.
1 of the studies in Alcoholism with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07482150Zealand University HospitalThe Connect Trial: Connecting Hospital Patients to Alcohol Care | 2027-09-01 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies in Alcoholism with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), approved for the treatment of type 2 diabetes and obesity, have shown promise as a novel treatment for alcohol use disorder (AUD). This study aims to investigate whether the Glucose-dependent Insulinotropic Polypeptide/GLP-1RA tirzepatide will reduce alcohol consumption in patients with a dual diagnosis of AUD and schizophrenia, a population in dire need of improved treatment options. To further investigate the neurobiological underpinnings of a potential dampening effect on alcohol consumption, functional magnetic resonance imaging (fMRI) brain scans will be applied.
The key anticipated outcomes include:
The study is a randomised (1:1), double-blinded, placebo-controlled clinical trial including 26 weeks of treatment investigating whether tirzepatide vs placebo can reduce the number of heavy drinking days in patients with comorbid diagnoses of schizophrenia and AUD. The primary endpoint will be evaluated after 16 weeks of treatment. The study will conclude after a post-intervention follow-up 14 weeks after last treatment at week 40 of the study.
108 participants will be included. Alcohol consumption and secondary endpoints will be assessed at weeks 0, 4, 8, 12, 16, 20, 26, and 40, and all patients will be offered 6 sessions of supportive therapy, while participating in the study.
The randomisation and administration of the weekly injections (tirzepatide/placebo) will be administered by an unblinded staff not involved in other trial activities. All patients will be blindfolded when receiving the injections. Eligible patients (n=50) will have an fMRI brain scan performed at baseline and in week 16. Blood tests for safety measures and secondary endpoint-measures will be performed at weeks 0, 16, 26, and 40.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis:
Exclusion Criteria:
For the subgroup of participants undergoing brain scans:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tirzepatide once-weekly s.c.titrated to a maximum dose of 15 mg
Drug: Tirzepatide
Saline s.c. once-weekly
Drug: Placebo
Once weekly injections s.c. with tirzepatide (Mounjaro(R))
Also known as: Mounjaro
Once weekly injections s.c. with placebo (BD Posiflush)
Also known as: BD Posiflush (saline)
Change in heavy drinking days
The primary endpoint will be a change in alcohol consumption, measured as a per cent change in heavy drinking days after 16 weeks of treatment with tirzepatide or placebo, adjusted for the value at baseline (percentage points). Heavy drinking days will be registered using the Timeline-Follow-Back (TLFB) method including the last 21 consecutive days with the largest total alcohol intake and the greatest number of heavy drinking days within the 28 days preceding the evaluation. A heavy drinking day is defined as more than 60/48 grams (men/women) of alcohol in one day.
Time frame: From baseline to 16 weeks of treatment
Heavy drinking days
Change in heavy drinking days measured using the TLFB method.
Time frame: From baseline to 26 weeks of treatment and 14 weeks post-intervention
Total alcohol consumption
Change in total alcohol consumption measured using the TLFB method.
Time frame: From baseline to 16 and 26 weeks of treatment and 14 weeks post-intervention
Days without alcohol consumption
Change in number of days without alcohol measured using the TLFB method.
Time frame: From baseline to 16 and 26 weeks of treatment and 14 weeks post-intervention
World Health Organization (WHO) Risk Levels of Alcohol Consumption
Change in WHO alcohol risk level measured using the TLFB method.
Time frame: From baseline to 16 and 26 weeks of treatment and 14 weeks post-intervention
Penn Alcohol Craving Scale (PACS) score
Change in Penn Alcohol Craving Scale (PACS) score. Minimum score = 0, maximum score =30. A high score means a worse outcome.
Time frame: From baseline to 16 and 26 weeks of treatment
Alcohol Use Disorder Identification Test (AUDIT) score
Change in AUDIT score. Minimum score = 0, maximum score =40. A high score means a worse outcome.
Time frame: From baseline to 16 and 26 weeks of treatment
Drug Use Disorders Identification Test (DUDIT) score
Change in DUDIT score. Minimum score = 0, maximum score =44. A high score means a worse outcome.
Time frame: From baseline to 16 and 26 weeks of treatment
Drug use frequency
Change in drug use frequency measured using the drug use frequency section of the DUDIT-extended
Time frame: From baseline to 16 and 26 weeks of treatment
Preferred substance of use
Change in preferred substance of use
Time frame: From baseline to 16 and 26 weeks of treatment
Biomarkers of cannabis exposure
Changes in biomarkers of recent cannabis exposure (blood 11-hydroxy-delta 9-tetrahydrocannabinol (11-OH-THC) and 11-nor-9-carboxy-delta 9-tetrahydrocannabinol (THCCOOH) levels)
Time frame: From baseline to 16 and 26 weeks of treatment
The Patient Health Questionnaire (PHQ-9)
Changes in PHQ-9
Time frame: From baseline to 16 and 26 weeks of treatment
Fagerströms Test for Nicotine Dependence score
Changes in smoking habits using the Fagerströms Test for Nicotine Dependence score
Time frame: From baseline to 16 and 26 weeks of treatment
Number of cigarettes smoked per day
Changes in average number of cigarettes smoked per day
Time frame: From baseline to 16 and 26 weeks of treatment
Cotinine levels
Change in blood cotinine levels
Time frame: From baseline to 16 and 26 weeks of treatment
Blood parameters
Changes in blood parameters (GGT, ALAT, MCV)
Time frame: From baseline to 16 and 26 weeks of treatment
Liver fibrosis (FIB-4 score)
Changes in FIB-4 score
Time frame: From baseline to 26 weeks of treatment
Blood phosphatidyl ethanol (PEth) levels
Changes in PEth levels
Time frame: From baseline to 16 and 26 weeks of treatment and 14 weeks post-intervention
Glycaemic control parameters
Changes in HbA1c levels
Time frame: From baseline to 16 and 26 weeks of treatment and 14 weeks post-intervention
Blood pressure
Change in blood pressure
Time frame: From baseline to 16 and 26 weeks of treatment
Body weight
Change in body weight
Time frame: From baseline to 16 and 26 weeks of treatment and 14 weeks post-intervention
Waist circumference
Change in waist circumference
Time frame: From baseline to 16 and 26 weeks of treatment
fMRI alcohol cue-reactivity
Changes in fMRI BOLD signals in response to alcohol cues in brain regions related to reward in a subgroup (n=50) of participants
Time frame: From baseline to 16 weeks of treatment
WHO-5 Subjective Well-Being Index
Changes in quality of life measured using the World Health Organization-Five Well-Being Index (WHO-5)
Time frame: From baseline to 26 weeks of treatment
Global Assessment of Psychosocial Disability (GAPD)
Changes in GAPD score
Time frame: From baseline to 26 weeks of treatment
Positive and Negative Syndrome Scale (PANSS-6)
Changes in symptom severity of schizophrenia measured using PANSS-6
Time frame: From baseline to 26 weeks of treatment
Clinical Global Impression Severity Scale (CGI-S)
Changes in CGI-S score
Time frame: From baseline to 26 weeks of treatment
Proteomics
Change in proteomics
Time frame: From baseline to 16 and 26 weeks of treatment
Qualitative experience
For a subgroup of participants (n=20), qualitative interviews will be performed after 16 weeks of treatment to evaluate qualitative differences in trial participation experiences between the intervention and placebo groups, which will be assessed as a secondary outcome.
Time frame: From baseline to 16 weeks of treatment
Safety Outcome
Suicidal ideation measured using the Columbia Suicide Severity Rating Scale (C-SSRS)
Time frame: From baseline to 16 and 26 weeks of treatment
Plan to share: Yes — IPD will be shared upon reasonable relevant requests, e.g. for meta-analyses or independent validations. IPD will be shared anonymized or de-identified to protect participants' privacy and in accordance with relevant regulations (GDPR).
Supporting information: Study protocol, Statistical analysis plan
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Aug 2028, 38 months after the start.
Of 123 non-industry phase 2 interventional studies under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 59. This study's planned 38 months is close to that.
Counting every sponsor, half of 135 studies reached it within 33 months; a quarter within 21 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide
Anders Fink-Jensen, MD, DMSci